Type III Osteogenesis Impurity (severe)
About
Osteogenesis Impurity (OI) is a group of inherited connective tissue diseases caused by mutations in the COL1A1 or COL1A2 gene that lead to abnormal synthesis of type I collagen. Type III is the most severe non-fatal type, with multiple fractures and severe skeletal deformities at birth. Core dilemmas: ① Repeated fractures lead to progressive skeletal deformities and short stature;② Scoliosis and thoracic deformities affect respiratory function;③ Bisphosphonates can reduce fractures but cannot cure them;④ There is currently no cure.
Features & Symptoms
- COL1A1/A2 gene mutation
- Multiple fractures at birth
- Severe skeletal deformity
- Short stature, scoliosis
Treatment Options
| Treatment | Description | Stage | Price Range |
|---|---|---|---|
| Intravenous bisphosphonate therapy | Intravenous infusion of pamidronate or zoledronic acid can increase bone mineral density and reduce the incidence of fractures. | 临床应用 | $50K - $150K/年 |
| Recombinant human parathyroid hormone (Teriparatide) | Promote bone formation and is suitable for adult patients with OI, but its use is limited in children. | 临床应用 | $80K - $200K/年 |
| Anti-sclerotin antibody (Romosozumab) | It promotes bone formation and inhibits bone resorption, and is currently in the OI clinical trial stage. | Phase II | $100K - $250K/年 |
Prognosis
Survive into adulthood, but severely disabled
Additional Notes
Notes: Fracture management: Conservative treatment should be mainly used for acute fractures, and elastic intramedullary nails should be used for internal fixation.(Fassier-Duval nail); Bisphosphonates treatment: Pamidronate disodium or zoledronic acid can increase bone mineral density and reduce fracture rate, and is recommended to be infused once every 3-6 months; Hearing monitoring: Patients with osteogenic insufficiency are often accompanied by conductive deafness, and annual hearing examinations are recommended; Cardiopulmonary monitoring: Severe OI can affect cardiopulmonary function, and regular lung function and cardiac ultrasound examinations are recommended; Spinal management: Scoliosis is common and requires regular evaluation and spinal fusion surgery if necessary. Exclusive service commitment: The platform will allocate a dedicated medical team to each patient to assist in dismantling and properly deploying the following precautions throughout the process. When cross-state and cross-border diagnosis and treatment projects or drugs are involved, the platform will make overall arrangements for the entire docking; for disabled and semi-disabled patient groups, the platform will provide rush-free alternative solutions (including remote consultation, door-to-door sampling, direct drug delivery in the cold chain, etc.), to ensure that patients can get the same high-quality diagnosis and treatment resources without having to travel in person.; Research stage: Clinical application. Prognosis: Survive into adulthood, but severely disabled.
Frequently Asked Questions
What is Type III Osteogenesis Impurity (severe)?
Osteogenesis Impurity (OI) is a group of inherited connective tissue diseases caused by mutations in the COL1A1 or COL1A2 gene that lead to abnormal synthesis of type I collagen. Type III is the most severe non-fatal type, with multiple fractures and severe skeletal deformities at birth. Core dilemmas: ① Repeated fractures lead to progressive skeletal deformities and short stature;② Scoliosis and thoracic deformities affect respiratory function;③ Bisphosphonates can reduce fractures but cannot cure them;④ There is currently no cure.
What are the symptoms of Type III Osteogenesis Impurity (severe)?
COL1A1/A2 gene mutation,Multiple fractures at birth,Severe skeletal deformity,Short stature, scoliosis
How is Type III Osteogenesis Impurity (severe) treated?
Intravenous bisphosphonate therapy: Intravenous infusion of pamidronate or zoledronic acid can increase bone mineral density and reduce the incidence of fractures.; Recombinant human parathyroid hormone (Teriparatide): Promote bone formation and is suitable for adult patients with OI, but its use is limited in children.; Anti-sclerotin antibody (Romosozumab): It promotes bone formation and inhibits bone resorption, and is currently in the OI clinical trial stage.
What is the prognosis for Type III Osteogenesis Impurity (severe)?
Survive into adulthood, but severely disabled